A novel Tn antigen epitope‑recognizing antibody for MUC1 predicts clinical outcome in patients with primary lung adenocarcinoma

Kato, Tatsuya; Ujiie, Hideki; Hatanaka, Kanako et al.

Oncology Letters, 2021, 21(3), 202

Permalink : https://hdl.handle.net/2115/83401

このアイテムのアクセス数:511件（2026-10-13 23:11 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
Oncol Lett 21(3) 202 pdf 2.74 MB 382

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権
open access
URI
https://hdl.handle.net/2115/83401
タイトル
A novel Tn antigen epitope‑recognizing antibody for MUC1 predicts clinical outcome in patients with primary lung adenocarcinoma
著者
Kato, Tatsuya ; Ujiie, Hideki ; Hatanaka, Kanako ; Nange, Ayae ; Okumura, Asami ; Tsubame, Kaho ; Naruchi, Kentato ; Sato, Masaharu ; Kaga, Kichizo ; Matsuno, Yoshihiro ; Wakasa, Satoru ; Hatanaka, Yutaka
著者名
Kato, Tatsuya
著者名
Ujiie, Hideki
著者名
Hatanaka, Kanako
著者名
Nange, Ayae
著者名
Okumura, Asami
著者名
Tsubame, Kaho
著者名
Naruchi, Kentato
著者名
Sato, Masaharu
著者名
Kaga, Kichizo
著者名
Matsuno, Yoshihiro
著者名
Wakasa, Satoru
著者名
Hatanaka, Yutaka
言語
英語
キーワード
mucin 1
Tn antigen
epitope‑defined antibody
epithelial‑mesenchymal transition
prognostic factor
lung cancer
発行日
2021-03-01
出版者
Spandidos Publications
収録物名
Oncology Letters
巻(号)
21(3)
ページ
202
抄録
Mucin 1 (MUC1) expression is upregulated in multiple types of cancer, including lung cancer. However, the conventional anti‑MUC1 antibody is not useful for the differentiation of malignant lung tumors and benign lesions due to its limited specificity. Our previous study screened a novel epitope‑defined antibody against cancer‑associated sugar chain structures that specifically recognizes the MUC1 Tn antigen (MUC1‑Tn ED Ab). In the present study, its potential utility as a diagnostic marker and therapeutic tool for lung adenocarcinoma (ADC) was examined. Immunohistochemical analysis of a lung ADC tissue microarray was performed using the MUC1‑Tn ED Ab (clone SN‑102), and the results were compared with those of another clone and commercially available MUC1 antibodies. The association between positive immunoreactivity of SN‑102 and clinicopathologic factors was analyzed. Furthermore, the association between MUC1‑Tn expression and epithelial‑mesenchymal transition markers and radiological characteristics was analyzed. Moderate or high MUC1‑Tn expression (MUC1‑Tn‑H) was observed in 138 (78.9%) of the 175 lung ADC cases. MUC1‑Tn‑H was associated with male sex, cigarette smoking, tumor extension, pleural invasion, and higher preoperative serum carcinoembryonic antigen and cytokeratin 19 fragment levels. Tumors with MUC1‑Tn‑H had higher consolidation/tumor ratios according to computed tomography and greater uptakes of 18F‑fluorodeoxyglucose. A total of 46 (26.9%) of the tumors had mesenchymal features, and MUC1‑Tn positivity was higher in the mesenchymal group than in the epithelial and intermediate groups (P<0.01 and P<0.01, respectively). Patients with tumors exhibiting MUC1‑Tn‑H had significantly shorter 5‑year overall and disease‑free survival times (P=0.011 and P<0.001, respectively). Additionally, MUC1‑Tn‑H was identified as an independent prognostic factor in multivariate analysis (P=0.024). MUC1‑Tn is specific for lung cancer cells and can improve diagnostic capabilities. Additionally, it may be a potential therapeutic target in lung ADC.
資源タイプ
学術雑誌論文
出版タイプ
Version of Record
権利情報
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
PISSN
1792-1074
EISSN
1792-1082
関連情報 (isIdenticalTo)
出版社版DOI
https://doi.org/10.3892/ol.2021.12463